A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

Hugh Young Rienhoff Jr,[1] Vip Viprakasit,[2] Lay Tay,[3] Paul Harmatz,[4] Elliott Vichinsky,[5] Deborah Chirnomas,[6] Janet L. Kwiatkowski,[7] Amy Tapper,[1] William Kramer,[1] John B. Porter,[8] and Ellis J. Neufeld[6]

[1]FerroKin BioSciences, Inc., San Carlos, CA, USA; [2]Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand; [3]IMVS, Division of Hematology, Adelaide, SA, Australia; [4]Hematology/Oncology, Children's Hospital & Research Center Oakland, Oakland, CA, USA; [5]Children's Hospital and Research Center Oakland, Oakland, CA, USA; [6]Hematology, Children's Hospital Boston, Boston, MA, USA; [7]Hematology Department, Children's Hospital, Philadelphia, PA, USA, and [8]Haematology, University College London, London, UK

Citation: Rienhoff HYJr, Viprakasit V, Tay L, Harmatz P, Vichinsky E, Chirnomas D, Kwiatkowski JL, Tapper A, Kramer W, Porter JB, and Neufeld EJ. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 2011;96(4):521-525. doi:10.3324/haematol.2010.034405

Online Supplementary Materials. (SEE PDF)